Evolution of the pharmaceutical market for nanoparticles

The earliest approvals of drugs applying nanotechnology date back to the 1980s, 1970s, and even the 1950s, with the authorization of several medicines whose characteristics and efficacy were based on their composition using nanocrystals [68,166-168]. Figure 3 illustrates the evolution of nanotechnology-based drug approvals over the years, while references [101,121,169,170] provide detailed lists of the approved products.

Figure 3.: Evolution of nanotechnology-based drug approvals (1955-2024). Number of approved nanomedicine products by material class across successive time periods. The data show an increase in approvals from the mid-1990s to the early 2000s, followed by relatively stable approval rates in later years, reflecting the establishment and consolidation of clinically successful nanomedicine platforms. Figure prepared by the authors based on information from references [101,121,169,170]

A report by Clogston and colleagues [147] provides an industry perspective on the current state of nanomedicine drug products based on the PharmaCircle™ database of pharmaceutical product pipelines and complemented by insights from companies active in nanotechnology-based pharmaceutical innovation. According to this industry-based analysis, nanocrystals represented the most prevalent nanomaterial type (38 %), followed by lipid nanoparticles (32 %) [147]. These observations are broadly consistent with U.S. Food and Drug Administration (FDA) data compiled between 1973 and 2015, in which liposomes (33 %) and nanocrystals (23 %) have been reported as the two most prevalent nanomaterial categories [171]. Minor differences in percentages may reflect sample representativeness, evolving formulation trends, or variations in classification criteria over time, particularly as lipid nanoparticle classifications have expanded beyond earlier liposome-focused categories.

Importantly, Clogston and colleagues [147] reported that commercially established products represent only 11 % of the overall nanomedicine portfolio, while most developments remain in preclinical or early clinical stages. Specifically, preclinical candidates account for 49 % of the lifecycle pipeline, whereas Phase I, II, and III clinical studies represent 12, 5 and 5 %, respectively [147].

Expanding the analysis beyond commercially established products to the broader development landscape reveals a marked shift in nanomaterial composition, with lipid-based nanoparticles increasing from approximately 28 to 32 % among marketed nanomedicines to 58 % of the overall pipeline [147]. This trend may reflect an increasing focus on lipid-based systems in current nanomedicine development.

From a therapeutic standpoint, cancer remains the leading focus of nanomedicine development. Nevertheless, an emerging trend is the diversification towards targeting infectious diseases and inflammatory, immune, and pain disorders. Emerging interest concentrates on central nervous system conditions, suggesting a more recent and rapidly growing area of therapeutic interest [147,171,172].

The market trends over the past three decades, together with advances in innovative therapies and increasing regulatory acceptance, suggest a promising future for nanotechnology-based developments [25,141,147]. Despite the high costs associated with these products [173,174], pharmaceutical companies are investing heavily in the development of nanotechnology platforms, indicating that nanotechnology will continue to have a major impact on the pharmaceutical market [121].

The increasing regulatory acceptance and expansion of nanomedicine pipelines are reflected not only in current market dynamics, but also in projections for the coming years. Figure 4 summarizes the approximate annual value of the nanotechnology-based therapeutic market over recent years, compiled from industry reports and published sources. For the upcoming years, the global market value estimates for these products are projected to reach up to USD 350 billion per year between 2026-2030 [63,170], while more aggressive scenarios indicate a potential market size above USD 420 billion annually by the end of this decade [175]. Collectively, the available evidence underscores the considerable potential for nanotechnology to continue impacting the pharmaceutical landscape, as translational barriers are progressively identified and addressed.

Figure 4.: Estimated evolution of the global nanomedicine market (2020-2025). Approximate annual market size estimates (USD millions) compiled by the authors from published studies and industry reports [175-180]. The market value observed in 2020 may reflect the immediate impact of the COVID-19 pandemic, likely associated with nanotechnology-based vaccine platforms